Supplementary Figure 1.png (301.61 kB)
Supplementary Figure 1. Real world assessment of myelodysplastic syndrome: Japanese claims data analysis
figure
posted on 2021-10-15, 15:08 authored by Saaya Tsutsué, Takahiro Suzuki, Hyojin Kim, Bruce CrawfordSupplementary Figure 1. Patient survival (A) overall (B) by age-group (C) by 1L. Patients were categorized by treatment regimen received in the 1L of therapy. AZA, azacitidine; ESA, erythropoiesis-stimulating agents.
